<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920918</url>
  </required_header>
  <id_info>
    <org_study_id>HM20007043</org_study_id>
    <secondary_id>28431754DIATBD</secondary_id>
    <nct_id>NCT02920918</nct_id>
  </id_info>
  <brief_title>Treatment of Diabetes in Patients With Systolic Heart Failure</brief_title>
  <official_title>A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs
      Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption [VO2])
      and ventilator efficiency (minute ventilation [VE]/carbon dioxide production [VCO2] slope) at
      cardiopulmonary exercise test (CPET) after 12 weeks of active treatment (primary endpoints).
      Blood pressure (BP), body water content, body composition, cardiac function, and diet will be
      also measured (secondary endpoints).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigator Initiated Study: Randomized, double-blinded, active-control clinical trial to
      determine the safety and efficacy of Canagliflozin and Sitagliptin in patients with type 2
      diabetes and systolic heart failure (HF).

      The investigators propose to study the effects of Canagliflozin 100 mg vs Sitagliptin 100 mg
      (both administered once daily for 12 weeks) on parameters of aerobic exercise capacity and
      ventilator efficiency by CPET after 12 weeks of active treatment. BP, body water content
      (Bioelectrical Impedance Analysis [BIA]), body composition (Dual-energy X-ray absorptiometry
      [DEXA]), cardiac function, diet and biomarkers will be also measured. Subjects with evidence
      of left ventricular hypertrophy will undergo cardiac magnetic resonance (CMR) imaging.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline aerobic exercise capacity at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>measured by cardiopulmonary exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline ventilator efficiency at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>measured by cardiopulmonary exercise test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>baseline, 4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body water content</measure>
    <time_frame>baseline, 4, 8 and 12 weeks</time_frame>
    <description>measured using bioelectrical impedance analysis (BIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>measured using dual-energy x-ray absorptiometry (DEXA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Canagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Canagliflozin will be administered orally in pill form at 100 mg, daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin will be administered orally in pill form at 100 mg, daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin</intervention_name>
    <arm_group_label>Canagliflozin</arm_group_label>
    <other_name>Invokana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Symptomatic stable heart failure (New York Heart Association (NYHA) functional
             classification II-III) with reduced left ventricular ejection fraction (LVEF) ≤40%

          -  Peak exercise limited by shortness of breath and associated with a respiratory
             exchange ratio (RER) &gt;1.00 (reflecting maximal aerobic effort);

          -  Poorly controlled Type 2 Diabetes Mellitus (T2DM)(HbA1c levels between 7.0% and 10.0%
             if on a treatment regimen including insulin, or between 6.5% and 10.0% if not on an
             insulin regimen);

          -  Eighteen years of age or older.

        Major Exclusion Criteria:

          -  Type I diabetes;

          -  Open label treatment with Sodium-GLucose coTransporter (SGLT)-2 inhibitors (within the
             past 3 months);

          -  Current treatment with thiazolidinedione (within the past 3 months);

          -  Chronic Renal Disease defined as Glomerular Filtration Rate (GFR) &lt;50 ml•min-1/1.73m2
             according to local laboratory

          -  Pregnancy or of child-bearing potential or lactating;

          -  Active or recent (within 2 weeks) genital/urinary infection;

          -  Concomitant conditions or treatment which would affect completion or interpretation of
             the study (i.e, physical inability to walk or run on a treadmill

          -  Inability to give informed consent.

        Exclusion criteria specific to the cardiac magnetic resonance (CMR) substudy.

          -  Estimated GFR &lt;60 ml•min-1/1.73m2

          -  Implantable cardioverter defibrillator, pacemaker or other implantable metal device
             not compatible with CMR scanning;

          -  Severe claustrophobia, inability to lay flat for up to 60 minutes, or other
             contraindication to CMR scanning.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <phone>804-828-0513</phone>
    <email>antonio.abbate@vcuhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salvatore Carbone, MS</last_name>
    <phone>804-628-3980</phone>
    <email>salvatore.carbone@vcuhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Abbate, MD, PhD</last_name>
      <phone>804-828-0513</phone>
      <email>antonio.abbate@vcuhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Salvatore Carbone, MS</last_name>
      <phone>804-628-3980</phone>
      <email>salvatore.carbone@vcuhealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systolic Heart Failure</keyword>
  <keyword>Canagliflozin</keyword>
  <keyword>Sitagliptin Phosphate</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <keyword>DPPIV inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators plan to present the data promptly upon analysis as an abstract to a national meeting and/or a manuscript.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

